Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Non-Hodgkin | 8 | 2022 | 260 | 2.580 |
Why?
|
| Lymphoma, Follicular | 5 | 2022 | 73 | 1.890 |
Why?
|
| Antineoplastic Agents | 6 | 2017 | 2303 | 0.970 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2017 | 43 | 0.930 |
Why?
|
| Thalidomide | 2 | 2017 | 55 | 0.770 |
Why?
|
| Rituximab | 3 | 2022 | 128 | 0.750 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 107 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2017 | 2544 | 0.660 |
Why?
|
| Lymphoma | 3 | 2008 | 247 | 0.640 |
Why?
|
| Stem Cell Transplantation | 3 | 2006 | 192 | 0.620 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 603 | 0.600 |
Why?
|
| Quinazolinones | 1 | 2017 | 15 | 0.510 |
Why?
|
| Purines | 1 | 2017 | 91 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 304 | 0.450 |
Why?
|
| Hodgkin Disease | 2 | 2013 | 145 | 0.420 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 215 | 0.400 |
Why?
|
| Sirolimus | 2 | 2012 | 176 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 78 | 0.370 |
Why?
|
| Maintenance Chemotherapy | 1 | 2012 | 91 | 0.350 |
Why?
|
| Drug Costs | 1 | 2012 | 66 | 0.350 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 537 | 0.290 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 134 | 0.290 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 278 | 0.290 |
Why?
|
| Recurrence | 5 | 2013 | 1190 | 0.280 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 392 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 1395 | 0.250 |
Why?
|
| Topotecan | 1 | 2006 | 46 | 0.240 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2013 | 939 | 0.230 |
Why?
|
| Doxorubicin | 1 | 2006 | 284 | 0.230 |
Why?
|
| Salvage Therapy | 1 | 2006 | 235 | 0.220 |
Why?
|
| Transplantation Conditioning | 1 | 2006 | 383 | 0.210 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 990 | 0.190 |
Why?
|
| Humans | 15 | 2022 | 93515 | 0.190 |
Why?
|
| Remission Induction | 3 | 2010 | 738 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2010 | 1170 | 0.180 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 829 | 0.170 |
Why?
|
| Immunologic Factors | 2 | 2015 | 176 | 0.170 |
Why?
|
| Aged | 7 | 2017 | 20434 | 0.170 |
Why?
|
| Middle Aged | 7 | 2017 | 27573 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2015 | 9099 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1161 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2009 | 292 | 0.140 |
Why?
|
| Male | 8 | 2017 | 44557 | 0.140 |
Why?
|
| Female | 8 | 2017 | 48702 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 259 | 0.120 |
Why?
|
| Adult | 6 | 2013 | 27918 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2009 | 1524 | 0.110 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 52 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 224 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 7061 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 107 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2009 | 1723 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2015 | 3502 | 0.100 |
Why?
|
| Everolimus | 1 | 2012 | 34 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 282 | 0.080 |
Why?
|
| Mucositis | 1 | 2010 | 18 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 366 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1448 | 0.080 |
Why?
|
| Antigens, CD20 | 1 | 2009 | 33 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 147 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2009 | 187 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2009 | 315 | 0.070 |
Why?
|
| Young Adult | 2 | 2013 | 6930 | 0.070 |
Why?
|
| Pneumonia | 1 | 2010 | 193 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2010 | 409 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 876 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 184 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 988 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 245 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 359 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2008 | 122 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1103 | 0.060 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2006 | 34 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2006 | 34 | 0.060 |
Why?
|
| Procarbazine | 1 | 2006 | 26 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2008 | 756 | 0.060 |
Why?
|
| Vinblastine | 1 | 2006 | 85 | 0.060 |
Why?
|
| Chicago | 1 | 2010 | 1464 | 0.060 |
Why?
|
| Prednisone | 1 | 2006 | 242 | 0.060 |
Why?
|
| Reoperation | 1 | 2008 | 702 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2006 | 208 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 641 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 3830 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 636 | 0.050 |
Why?
|
| Time Factors | 1 | 2006 | 5410 | 0.030 |
Why?
|
| Adolescent | 1 | 2008 | 9606 | 0.030 |
Why?
|